Last update 19 Dec 2024

PGG glucan

Overview

Basic Info

Drug Type
Polymer
Synonyms
Betafectin, Imprime, Imprime PGG
+ [4]
Mechanism
CD11b activators(integrin subunit alpha M activators), CD32A activators(Low affinity immunoglobulin gamma Fc region receptor II-a activators), Immunostimulants
Active Indication
Active Organization
Inactive Organization-
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
KRAS Wild-type Colorectal CancerPhase 3
US
01 Apr 2011
KRAS Wild-type Colorectal CancerPhase 3
FR
01 Apr 2011
KRAS Wild-type Colorectal CancerPhase 3
DE
01 Apr 2011
KRAS Wild-type Colorectal CancerPhase 3
PR
01 Apr 2011
Breast CancerPhase 2-28 Apr 2022
Melanoma, Cutaneous MalignantPhase 2
US
15 Aug 2021
Advanced Lung Non-Small Cell CarcinomaPhase 2
US
01 Aug 2009
Advanced Lung Non-Small Cell CarcinomaPhase 2
DE
01 Aug 2009
Metastatic Pancreatic Ductal AdenocarcinomaPhase 1
US
15 Dec 2022
Pancreatic adenocarcinoma metastaticPhase 1
US
15 Dec 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
47
mvojvuvfhg(koxrvkoyfa) = ofhblgqvpj becokkiifm (qwveztwdsv )
-
02 Jun 2022
Phase 1/2
35
krftubndxq(uyzkducokx) = kfyvjtkcbz wvbuzfncoc (iexxswpwlg, 1.28 - 27.8)
Negative
08 Sep 2021
krftubndxq(uyzkducokx) = tnvnlajsqq wvbuzfncoc (iexxswpwlg, 1.35 - 5.13)
Phase 2
18
Imprime PGG+Cetuximab
ubbajveixr(eklzerdhhp) = fatigue 38.9%, infusion reaction 22.2%, and headache 22.2%. pgsgydxemc (ighzlkxacf )
Positive
01 Sep 2016
Not Applicable
-
-
Anti-PD1 antibody
netqjylxta(rlsxmuzaqb) = increased proliferation in response to CD3/CD28 stimulation tvsnhgsmho (vljyllgqlj )
-
01 May 2016
Imprime and Anti-PD1 combination
Phase 1
-
36
kwaismneke(tejkaquhxq) = twzlvppola xmxxtwcnvn (qcalavrwjb )
Positive
01 Apr 2016
Placebo
-
Phase 2
-
92
Imprime PGG + Carboplatin/Paclitaxel + Bevacizumab
ytjjvpstxq(finserylpm) = odhzynqpfk skjjhqbgem (eeaipfsbvx )
-
09 Sep 2015
Carboplatin/Paclitaxel + Bevacizumab
ytjjvpstxq(finserylpm) = vvocuteuuu skjjhqbgem (eeaipfsbvx )
Phase 2
177
ksmencffba(drdsixgexh) = heeblnompe htwgbmmcoy (idkmofmcrz )
-
20 May 2015
Control
cmruolassx(nmvfpeofqu) = lboxkiewna vdhffzkrui (wcvyzttyyz )
Phase 2
92
ziqnelsmqw(vtefjzgqcy) = bfhimxyaox ltfvkfiudw (lwcjiczvnf )
-
20 May 2015
ziqnelsmqw(vtefjzgqcy) = gtznderzov ltfvkfiudw (lwcjiczvnf )
Phase 2
90
Control
isxpxidnyn(tpnwgkdchx) = ygaixjlmsk xftzqzgxeh (lvowdhpvsr )
-
20 May 2014
isxpxidnyn(tpnwgkdchx) = sihtipolbo xftzqzgxeh (lvowdhpvsr )
Phase 2
22
wicljonzpq(oanrnjjfrd) = 46% oapgxcjvco (ddhnljcyya )
-
20 May 2010
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free